AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

Abstract Endocrine therapy (ET) in combination with CDK4/6 inhibition is routinely used as first-line treatment for HR+/HER2− metastatic breast cancer (MBC) patients. However, 30–40% of patients quickly develop disease progression. In this open-label multicenter clinical trial, we utilized a hypothe...

Full description

Bibliographic Details
Main Authors: Maysa M. Abu-Khalaf, K. Alex Hodge, Christos Hatzis, Elisa Baldelli, Emna El Gazzah, Frances Valdes, William M. Sikov, Monica M. Mita, Neelima Denduluri, Rita Murphy, Daniel Zelterman, Lance Liotta, Bryant Dunetz, Rick Dunetz, Emanuel F. Petricoin, Mariaelena Pierobon
Format: Article
Language:English
Published: Nature Portfolio 2023-02-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-023-00360-5

Internet

https://doi.org/10.1038/s41698-023-00360-5

Similar Items